- Home
- GERN vs OLMA Comparison
GERN vs OLMA Comparison
Compare GERN & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GERN | OLMA |
|---|---|---|
| Founded | 1990 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 949.3M |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GERN | OLMA |
|---|---|---|
| Price | $1.31 | $9.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $2.17 | ★ $44.89 |
| AVG Volume (30 Days) | ★ 8.8M | 823.9K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.85 | 15.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,065,000.00 | N/A |
| Revenue This Year | $26.91 | N/A |
| Revenue Next Year | $43.75 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.04 | $6.65 |
| 52 Week High | $2.01 | $36.26 |
Technical Indicators
Market Signals| Indicator | GERN | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 39.30 | 37.07 |
| Support Level | $1.24 | $9.06 |
| Resistance Level | $1.32 | $11.27 |
| Average True Range (ATR) | 0.07 | 0.54 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 10.00 | 9.77 |
Price Performance
Historical ComparisonAbout GERN Geron Corporation
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.